NMS Labs Testing Helps to Enforce DEA Control of Synthetic Marijuana

WILLOW GROVE, Pa.--()--In an announcement last week, the U.S. Drug Enforcement Administration (DEA) placed the synthetic cannabinoid, MAB–CHMINACA (also known as ADB–CHMINACA), into Schedule I pursuant to the temporary scheduling provisions of the Controlled Substances Act. The same category as heroin and LSD, this announcement recognizes the risk presented by this drug and a level of concern about its effects.

The synthetic cannabinoid drug class, sometimes known as fake weed and sold under brand names such as “K2” and “Spice”, has been linked to an alarming increase in reports of illness, hospitalizations and even death in the United States. This action by the DEA emphasizes the need to be able to test blood and urine for synthetic marijuana use. Currently, the synthetic cannabinoid drugs present in these substances are undetectable in routine drug tests.

NMS Labs added ADB-CHMINACA to the scope of its synthetic cannabinoids test earlier this year, after monitoring the market place and the latest designer drug trends. By observing drug user web sites, law enforcement data, reports to emergency rooms, international scientific research studies, and many other sources, NMS Labs actively manages the scope of its tests to ensure that testing is relevant to today’s illicit designer drug market and associated investigations. NMS Labs Chief of Forensic Toxicology, Dr. Barry Logan explained, “The synthetic cannabinoid marketplace continues to evolve at a breakneck speed, with new compounds appearing in treatment, Emergency Room, DUID arrest, and medical examiner populations every few weeks. Progressive companies concerned about safety in the workplace are also starting to add synthetic cannabinoid testing to pre-employment screens.”

Dr. Logan further commented, “The list of adverse effects is growing rapidly and includes neurological effects such as anxiety, paranoia, and agitation, as well as tremor, seizures, tachycardia, and hypertension. Getting to the root cause of these symptoms in decedents, intoxicated patients and arrestees is critical from both a public health and criminal justice perspective, and makes it essential you are using the most current test.”

Drug users are always looking for any means to get high, but still beat the routine drug test, and current testing helps to close that particular loophole. NMS Labs works diligently to provide law enforcement and others with rapid turnaround time and informed client communication, and backs all that up with defensible expert testimony in court.

About NMS Labs

NMS Labs is an international forensic and clinical reference laboratory that is unsurpassed in its scope of toxicology tests, accuracy of results, scientific expertise, and innovation. Dedicated to staying ahead of the curve for this new class of drugs, The NMS Labs Designer Drug Strategy Team was created in 2011. This team has consistently tracked the changing synthetic cannabinoid market, identifying novel and emerging drugs and anticipating the most popular new substances. NMS Labs is passionate about promoting public health and safety. For more information on NMS Labs, please visit www.nmslabs.com.

Contacts

NMS Labs
Amanda Shirk, Marketing, 215-366-1405

Release Summary

NMS Labs Testing Helps to Enforce DEA Control of Synthetic Marijuana

Contacts

NMS Labs
Amanda Shirk, Marketing, 215-366-1405